AbTis

AbTis operates in the biopharmaceutical sector, focusing on the development and production of Antibody-Drug Conjugates (ADCs). The company offers a proprietary linker platform that enhances the conjugation process, ensuring high yield and simplified purification. This approach not only reduces production costs but also increases the therapeutic index of ADCs. AbTis collaborates with both industrial and academic partners, providing them with the ability to verify the druggability of novel ADCs within a short timeframe of 2-3 weeks. The business model revolves around partnerships and collaborations, where AbTis leverages its technology to assist in ADC development, thereby generating revenue through service agreements and licensing. The company serves clients in the pharmaceutical and biotechnology industries, aiming to streamline ADC development and enhance therapeutic outcomes. Keywords: ADC, linker platform, biopharmaceutical, conjugation, purification, therapeutic index, collaboration, druggability, partnerships, revenue.